[go: up one dir, main page]

PE20150200A1 - Formulacion de anticuerpos - Google Patents

Formulacion de anticuerpos

Info

Publication number
PE20150200A1
PE20150200A1 PE2014002437A PE2014002437A PE20150200A1 PE 20150200 A1 PE20150200 A1 PE 20150200A1 PE 2014002437 A PE2014002437 A PE 2014002437A PE 2014002437 A PE2014002437 A PE 2014002437A PE 20150200 A1 PE20150200 A1 PE 20150200A1
Authority
PE
Peru
Prior art keywords
antibodies
formulation
refers
composition
aqueous
Prior art date
Application number
PE2014002437A
Other languages
English (en)
Inventor
Marta Cosenza
Christoph Stark
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48914378&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20150200(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20150200A1 publication Critical patent/PE20150200A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION ACUOSA QUE COMPRENDE: LOS ANTICUERPOS ANTI-BAFFR , DICHA COMPOSICION ES UTIL PARA EL TRATAMIENTO DE UNA ENFERMEDAD AUTOINMUNE. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA ACUOSA PUEDE INCLUIR UNO O MAS AZUCARES, UN AGENTE AMORTIGUADOR, UN SURFACTANTE, Y/O UN AMINOACIDO LIBRE
PE2014002437A 2012-06-12 2013-06-11 Formulacion de anticuerpos PE20150200A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261658472P 2012-06-12 2012-06-12

Publications (1)

Publication Number Publication Date
PE20150200A1 true PE20150200A1 (es) 2015-02-08

Family

ID=48914378

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014002437A PE20150200A1 (es) 2012-06-12 2013-06-11 Formulacion de anticuerpos

Country Status (35)

Country Link
US (4) US9216219B2 (es)
EP (2) EP2858671B1 (es)
JP (1) JP6265978B2 (es)
KR (1) KR102124820B1 (es)
CN (1) CN104363920B (es)
AR (1) AR091413A1 (es)
AU (1) AU2013276112B2 (es)
BR (1) BR112014030820B1 (es)
CA (1) CA2875386C (es)
CL (1) CL2014003370A1 (es)
CO (1) CO7151487A2 (es)
CY (1) CY1122181T1 (es)
DK (1) DK2858671T3 (es)
EA (1) EA033373B1 (es)
EC (1) ECSP15017314A (es)
ES (1) ES2751659T3 (es)
GT (1) GT201400285A (es)
HR (1) HRP20191827T1 (es)
HU (1) HUE045523T2 (es)
IL (1) IL235966B (es)
LT (1) LT2858671T (es)
MA (1) MA37616A1 (es)
MX (1) MX363380B (es)
MY (1) MY179818A (es)
NZ (1) NZ630885A (es)
PE (1) PE20150200A1 (es)
PH (1) PH12014502778A1 (es)
PL (1) PL2858671T3 (es)
PT (1) PT2858671T (es)
SG (1) SG11201408174UA (es)
SI (1) SI2858671T1 (es)
TN (1) TN2014000488A1 (es)
TW (1) TWI653983B (es)
WO (1) WO2013186700A1 (es)
ZA (1) ZA201408547B (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE057244T2 (hu) 2010-01-06 2022-04-28 Takeda Pharmaceuticals Co Plazma kallikreint kötõ fehérjék
WO2012076670A2 (en) 2010-12-10 2012-06-14 Novartis Ag Antibody formulation
AU2012204202A1 (en) 2011-01-06 2013-07-11 Dyax Corp. Plasma kallikrein binding proteins
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
TWI660972B (zh) 2012-09-10 2019-06-01 愛爾蘭商尼歐托普生物科學公司 抗ｍｃａｍ抗體及相關使用方法
JP2016513682A (ja) 2013-03-15 2016-05-16 ダイアックス コーポレーション 抗血漿カリクレイン抗体
US10513555B2 (en) * 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
CN104730237A (zh) * 2013-12-23 2015-06-24 国家纳米科学中心 试纸及其应用以及检测甲胎蛋白抗原、乙肝表面抗原或HIV的gp41抗体的方法
KR102903403B1 (ko) 2014-01-21 2025-12-24 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질 및 유전성 혈관부종을 치료하는 데 있어서의 이의 용도
ES2744526T3 (es) 2014-03-12 2020-02-25 Prothena Biosciences Ltd Anticuerpos anti-MCAM y métodos de uso asociados
US10059761B2 (en) 2014-03-12 2018-08-28 Prothena Biosciences Limited Anti-Laminin4 antibodies specific for LG4-5
US10428158B2 (en) 2014-03-27 2019-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
KR101597037B1 (ko) 2014-06-26 2016-02-24 엘지디스플레이 주식회사 구동소자의 전기적 특성 편차를 보상할 수 있는 유기발광 표시장치
TWI806150B (zh) 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
EP3916020A1 (en) * 2015-03-30 2021-12-01 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack
WO2017046776A2 (en) * 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
EA201891339A1 (ru) * 2015-12-07 2019-01-31 Мерк Патент Гмбх Водный фармацевтический препарат, который содержит антитело к pd-l1 авелумаб
JP7003354B2 (ja) 2015-12-11 2022-03-04 武田薬品工業株式会社 遺伝性血管性浮腫の発作を治療するための血漿カリクレイン阻害薬およびその用途
JP6897570B2 (ja) 2015-12-18 2021-06-30 アステラス製薬株式会社 抗ヒトｔｓｌｐ受容体抗体含有医薬組成物
KR102389489B1 (ko) * 2016-06-16 2022-04-22 얀센 백신스 앤드 프리벤션 비.브이. Hiv 백신 제형
KR20240000650A (ko) 2016-10-19 2024-01-02 인벤라 인코포레이티드 항체 구조물
AU2017383142A1 (en) 2016-12-22 2019-07-04 Università Degli Studi Magna Graecia Catanzaro A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of CD43
JP2020509025A (ja) * 2017-03-01 2020-03-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ モノクローナル抗体製剤
TW201834639A (zh) * 2017-03-06 2018-10-01 德商馬克專利公司 水性抗體調配物
CN110831621A (zh) * 2017-04-18 2020-02-21 雷迪博士实验室有限公司 稳定的液体药物组合物
JOP20190260A1 (ar) * 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
SI3658184T1 (sl) * 2017-07-27 2024-01-31 Alexion Pharmaceuticals, Inc., Formulacije z visoko koncentracijo protiteles proti-C5
JOP20200041A1 (ar) * 2017-08-22 2020-02-20 Biogen Ma Inc تركيبات صيدلية تحتوي على أجسام مضادة لبيتا نشوي
CU20200022A7 (es) 2017-10-06 2021-01-12 Prothena Biosciences Ltd Métodos para detectar transtiretina
EP3717512A4 (en) * 2017-11-29 2021-08-25 Prothena Biosciences Limited LYOPHILIZED FORMULATION OF A MONOCLONAL ANTIBODY AGAINST TRANSTHYRETIN
EP3802580A1 (en) 2018-06-05 2021-04-14 King's College London Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system
WO2020006266A1 (en) 2018-06-28 2020-01-02 Alexion Pharmaceuticals, Inc. Methods of producing anti-c5 antibodies
EP3897714A1 (en) 2018-12-18 2021-10-27 Novartis AG Protein solution formulation containing high concentration of an anti-vegf antibody
UA128098C2 (uk) 2019-02-18 2024-04-03 Елі Ліллі Енд Компані Водна фармацевтична композиція антитіла проти il-17a
EP3932426A4 (en) * 2019-02-26 2022-12-14 Innovent Biologics (Suzhou) Co., Ltd. PREPARATIONS CONTAINING AN ANTI-CD47 ANTIBODY, METHOD FOR THE PREPARATION AND USE THEREOF
EP4055047A1 (en) 2019-11-06 2022-09-14 Novartis AG Treatment for sjögren's syndrome
CN113116812A (zh) * 2019-12-30 2021-07-16 百奥泰生物制药股份有限公司 含抗Trop2抗体-药物偶联物的制剂及其制备方法和应用
WO2021146160A1 (en) 2020-01-13 2021-07-22 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack
JP2023511356A (ja) * 2020-01-21 2023-03-17 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド 組換え完全ヒト抗ｔｉｇｉｔモノクローナル抗体製剤及びその調製方法と使用
AU2021320129B2 (en) * 2020-08-04 2025-12-18 Novartis Ag Treatment of B cell malignancies
WO2022031568A1 (en) * 2020-08-04 2022-02-10 Novartis Ag Treatment of cll
AU2021404495A1 (en) * 2020-12-17 2023-07-27 Astrazeneca Ab Anti-il5r antibody formulations
CN115073598B (zh) * 2021-03-15 2024-02-20 盛禾(中国)生物制药有限公司 一种抗baffr抗体及其应用
EP4334352A1 (en) 2021-05-04 2024-03-13 Novartis AG Treatment for lupus nephritis using anti-baffr antibodies
CA3215919A1 (en) 2021-05-04 2022-11-10 Novartis Ag Treatment for systemic lupus erythematosus using anti-baffr antibodies
MX2024003913A (es) * 2021-09-29 2024-04-26 Dragonfly Therapeutics Inc Anticuerpos dirigidos al receptor del factor activador de celulas b (baff-r) y uso de los mismos.
JP2025538151A (ja) 2022-11-07 2025-11-26 アップストリーム バイオ インコーポレイテッド 抗ヒトｔｓｌｐ受容体抗体を含む医薬組成物及びその使用方法
CN118681009A (zh) * 2023-03-21 2024-09-24 百奥泰生物制药股份有限公司 一种复方制剂及其应用
CN116712390B (zh) * 2023-08-04 2023-11-14 上海览屹医药科技有限公司 一种高浓度高稳定性的抗体制剂及其制备方法
WO2025257781A1 (en) * 2024-06-14 2025-12-18 Novartis Ag Treatment of systemic sclerosis using anti-baff-r antibodies
WO2025263459A1 (ja) * 2024-06-17 2025-12-26 学校法人神戸薬科大学 バイオ医薬品組成物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US20020077461A1 (en) 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
PT1914244E (pt) 1999-04-09 2013-07-26 Kyowa Hakko Kirin Co Ltd Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico
EP1192243A4 (en) 1999-06-23 2003-05-28 Univ Oregon Health & Science METHOD FOR REINFORCING HEMATOPOIESE
NZ523476A (en) 2000-06-28 2004-04-30 Glycofi Inc Methods for humanizing glycosylation of recombinant glycoproteins expressed in lower eukaryotes
DK1443961T3 (da) 2001-10-25 2009-08-24 Genentech Inc Glycoprotein-sammensætninger
WO2003039485A2 (en) 2001-11-08 2003-05-15 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
EP3210624A1 (en) 2002-02-27 2017-08-30 Immunex Corporation Stabilized tnfr-fc composition comprising arginine
WO2004055164A2 (en) 2002-12-13 2004-07-01 Abgenix, Inc. System and method for stabilizing antibodies with histidine
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CN101120021A (zh) * 2004-12-31 2008-02-06 基因技术公司 结合br3的多肽及其用途
GEP20146129B (en) 2008-07-17 2014-08-11 Novartis Ag Compositions and methods of therapeutic antibodies usage
ES2532007T3 (es) * 2009-11-17 2015-03-23 Ipsen Pharma S.A.S. Formulación para combinación de HGH y rhIGF-1
WO2012076670A2 (en) 2010-12-10 2012-06-14 Novartis Ag Antibody formulation
WO2013083497A1 (en) 2011-12-06 2013-06-13 F. Hoffmann-La Roche Ag Antibody formulation
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation

Also Published As

Publication number Publication date
JP6265978B2 (ja) 2018-01-24
EP3593814A1 (en) 2020-01-15
US10689451B2 (en) 2020-06-23
PH12014502778B1 (en) 2015-02-02
SG11201408174UA (en) 2015-01-29
CA2875386C (en) 2022-09-13
KR102124820B1 (ko) 2020-06-22
GT201400285A (es) 2015-10-15
US9751951B2 (en) 2017-09-05
KR20150029683A (ko) 2015-03-18
AR091413A1 (es) 2015-02-04
US20130344088A1 (en) 2013-12-26
EA201492292A1 (ru) 2015-04-30
AU2013276112A1 (en) 2014-12-18
PT2858671T (pt) 2019-10-28
MX2014015262A (es) 2015-06-23
US20180251564A1 (en) 2018-09-06
PH12014502778A1 (en) 2015-02-02
ECSP15017314A (es) 2018-06-30
LT2858671T (lt) 2019-10-25
CY1122181T1 (el) 2020-11-25
PL2858671T3 (pl) 2020-01-31
EP2858671B1 (en) 2019-07-24
IL235966A0 (en) 2015-01-29
EP3593814B1 (en) 2026-01-21
CA2875386A1 (en) 2013-12-19
CN104363920A (zh) 2015-02-18
ZA201408547B (en) 2015-12-23
US20180051092A1 (en) 2018-02-22
CO7151487A2 (es) 2014-12-29
EP2858671A1 (en) 2015-04-15
MX363380B (es) 2019-03-21
TN2014000488A1 (en) 2016-03-30
US20160145341A1 (en) 2016-05-26
CL2014003370A1 (es) 2015-02-06
AU2013276112B2 (en) 2015-07-09
MA37616A1 (fr) 2017-08-31
CN104363920B (zh) 2018-05-04
HK1203146A1 (en) 2015-10-23
BR112014030820A2 (pt) 2017-07-25
WO2013186700A1 (en) 2013-12-19
ES2751659T3 (es) 2020-04-01
EA033373B1 (ru) 2019-10-31
TW201402144A (zh) 2014-01-16
TWI653983B (zh) 2019-03-21
SI2858671T1 (sl) 2019-11-29
US9216219B2 (en) 2015-12-22
MY179818A (en) 2020-11-16
JP2015521593A (ja) 2015-07-30
NZ630885A (en) 2016-01-29
DK2858671T3 (da) 2019-10-21
BR112014030820B1 (pt) 2023-02-07
HUE045523T2 (hu) 2020-01-28
HRP20191827T1 (hr) 2019-12-27
IL235966B (en) 2020-05-31

Similar Documents

Publication Publication Date Title
PE20150200A1 (es) Formulacion de anticuerpos
CL2015001984A1 (es) (divisional de la sol. 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos.
BR112013032717A2 (pt) coagonistas do receptor de glucagon/glp-1
CL2016000882A1 (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso (divisional de sol. n°2710-15).
CL2016002812A1 (es) Uso de ácido 3-2,3,5,6-tetrafluoro-3-trifluorometoxi-bifenil-4-ilcarbamoil-tiofeno-2-carboxílico para preparar un medicamento útil para tratar una enfermedad ocular que es uveítis, ojo seco o causada por un adenovirus composición formulación.
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
PE20141672A1 (es) FORMULACION PARA ANTICUERPO ANTI-alfa4�7
CL2012000269A1 (es) Formulacion farmaceutica inyectable subcutanea altamente concentrada de un anticuerpo anti-her2 que comprende dicho anticuerpo, un amortiguador, un estabilizador, un tensioactivo no ionico y una enzima hialuronidasa; dispositivo de inyeccion; kit y uso de la formulacion para tratar enfermedades tales como cancer.
CR20140365A (es) Compuestos de carbamato y preparación y uso de los mismos
UY35040A (es) Pirrolopirimidinilamino-benzotiazolonas sustituidas
AR098168A1 (es) Formulación estable de insulina glulisina
BR112015000520A2 (pt) agente de espessamento estável com lipase
MX2017016345A (es) Proteinas de fusion para inhibir la angiogenesis.
UY32409A (es) Compuesto de anillo fusionado y su uso
CR20140579A (es) Composicion herbicida que tiene actividad herbicida mejorada
CL2011002229A1 (es) Formulacion farmaceutica que comprende un compuesto activo miembro de la familia de las calcitoninas que no es amilina.
BR112015014885A2 (pt) combinação de agentes ativos, composição cosmética e/ou dermatológica e processo para a preparação de uma composição de agentes ativos.
DOP2016000007A (es) Pirazolpiridinas sustituidas
CL2013001935A1 (es) Formulacion ácida acuosa que comprende un primer péptido enlazado a fluorocarburo; metodo para obtener dicha formulación; uso de dicha formulación para tratar o prevenir infeccion patógena, una enfermedad autoinmunitaria o cancer.
EA201891783A1 (ru) Композиция для растворения аморфных дитиазинов и способ ее применения
AR091739A1 (es) Composiciones y metodos para reducir el riesgo cardiometabolico
BR112015023161A2 (pt) derivados de piridin-4-ila
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
PE20141584A1 (es) Uso de un inhibidor de aromatasa para el tratamiento del hipogonadismo y enfermedades relacionadas

Legal Events

Date Code Title Description
FD Application declared void or lapsed